The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction
Carsten Goessl(Amgen (United States)), Rachel B. Wagman(Amgen (United States)), William C. Dougall(Queensland University of Technology), Leonid Katz(Amgen (United States)), Holly Brenza Zoog(Amgen (United States)), Paul J. Kostenuik(Amgen (United States)), Ada Braun(National Cancer Centre Japan), Roger Dansey(Memorial Sloan Kettering Cancer Center)
Cited by 41
Related Papers
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.4k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
RANK is essential for osteoclast and lymph node development
|Genes & Development|1999|1.5k